These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study.
    Author: Vos MJ, Postma TJ, Martens F, Uitdehaag BM, Blankenstein MA, Vandertop WP, Slotman BJ, Heimans JJ.
    Journal: Anticancer Res; 2004; 24(4):2511-4. PubMed ID: 15330206.
    Abstract:
    BACKGROUND: Serum levels of S-100B protein (S-100B) and neuron-specific enolase (NSE) are elevated after various cerebral injuries and are considered markers of central nervous system damage. In brain tumor patients, literature data on the prognostic value of serum S-100(B) and NSE levels are scarse and conflicting. PATIENTS AND METHODS: We assessed serum S-100B and NSE levels in 20 consecutive cerebral glioma patients, and evaluated serum levels in relation to survival to determine their prognostic value. Kaplan-Meier survival curves were constructed for patients with "high" (> median value) versus "low" (< or = median value) serum S-100B and NSE levels. RESULTS: A statistically significant shorter survival was found in patients with high serum S-100B levels, whereas a similar classification of patients based on serum NSE levels demonstrated no statistically significant difference in survival between the two groups. CONCLUSION: These preliminary data suggest that serum S-100B might be a prognostic variable in cerebral glioma patients. Further study is warranted to evaluate whether serum S-100B is an additional, independent prognostic variable.
    [Abstract] [Full Text] [Related] [New Search]